After Five Failed Clinical Trials, Will HLB's Eye Drug Turn Things Around with Its November US Phase 3 Results?
Predicted impact: Medium· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
US Phase 3 eye drug result due in November; company revenue is small versus its value.